Ultragenyx Pharmaceutical Inc. (RARE): Price and Financial Metrics

RARE POWR Grades

• RARE scores best on the Sentiment dimension, with a Sentiment rank ahead of 73.15% of US stocks.
• RARE's strongest trending metric is Stability; it's been moving up over the last 179 days.
• RARE ranks lowest in Momentum; there it ranks in the 12th percentile.

RARE Stock Summary

• For RARE, its debt to operating expenses ratio is greater than that reported by merely 10.7% of US equities we're observing.
• RARE's price/sales ratio is 14.12; that's higher than the P/S ratio of 89.73% of US stocks.
• Over the past twelve months, RARE has reported earnings growth of 144.38%, putting it ahead of 86.06% of US stocks in our set.
• Stocks with similar financial metrics, market capitalization, and price volatility to Ultragenyx Pharmaceutical Inc are FDMT, SLDB, MTEM, RGNX, and SRRK.
• Visit RARE's SEC page to see the company's official filings. To visit the company's web site, go to www.ultragenyx.com.

RARE Valuation Summary

• In comparison to the median Healthcare stock, RARE's EV/EBIT ratio is 161.43% lower, now standing at -18.
• RARE's price/earnings ratio has moved up 5 over the prior 92 months.
• Over the past 92 months, RARE's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for RARE.

RARE Growth Metrics

Its year over year cash and equivalents growth rate is now at 28.71%.
• The year over year net income to common stockholders growth rate now stands at 52.07%.
• Its 4 year net cashflow from operations growth rate is now at -158.8%.

Over the past 15 months, RARE's revenue has gone up $136,325,000.

The table below shows RARE's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	351.406	-338.695	-454.025
2021-09-30	359.559	-346.803	-355.578
2021-06-30	359.382	-349.121	-351.425
2021-03-31	334.116	-196.414	-203.682
2020-12-31	271.03	-132.22	-186.566
2020-09-30	215.081	-141.807	-256.36

RARE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• RARE has a Quality Grade of D, ranking ahead of 11.33% of graded US stocks.
• RARE's asset turnover comes in at 0.234 -- ranking 185th of 681 Pharmaceutical Products stocks.
• ADMS, AVDL, and QGEN are the stocks whose asset turnover ratios are most correlated with RARE.

The table below shows RARE's key quality metrics over time.